pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
